Mental wellbeing
Heated tobacco products: tobacco aerosol and reduced-exposure claims
On this page
Heated tobacco products heat processed tobacco to create an inhaled aerosol. They differ from nicotine e-cigarettes, which heat liquid. Heating changes the emissions compared with burning cigarettes, but the product still supplies nicotine and exposes users and bystanders to chemicals. A smoke-free description is not a clean-air or harmlessness finding.[1]
Product categories and the comparison that matters
| Category | Exposure or purpose | Boundary |
|---|---|---|
| Heated tobacco | Aerosol produced from tobacco leaf or sheet | Still a nicotine-containing tobacco product[1] |
| Nicotine e-cigarette | Aerosol produced from liquid | Different preparation and evidence base[2] |
| Reduced-exposure claim | Lower body exposure to specified harmful chemicals | Not equivalent to demonstrated reduction in disease[4] |
| Tobacco abstinence | Stopping tobacco-product exposure | The comparator differs from continuing cigarettes[5] |
Lower levels of some chemicals do not describe the entire mixture
A 2023 review of composition and toxicity reported lower levels of many toxic chemicals than in cigarette smoke, but also chemicals higher than in smoke or absent from the measured cigarette mixture. Products and testing methods differ. A count of reduced substances does not weight their biological effects or account for every constituent. The review also noted a predominance of tobacco-industry data and limited independent short-term research, which affect confidence in broad safety narratives.[3]
Avoiding combustion does not remove nicotine dependence
CDC states that heated tobacco contains nicotine regardless of whether heat is produced electronically or by flame. Nicotine is addictive, and developing brains require particular protection. The route can preserve familiar smoking routines while changing chemical exposure. A product’s ability to satisfy cravings is not evidence that it treats dependence or will lead to abstinence. People who have never used tobacco should not interpret product innovation or discreet use as a reason to begin.[1]
Evidence & uncertainty
Cochrane’s 2022 review found lower exposure to selected toxicants compared with cigarettes, but higher exposure than attempting tobacco abstinence. None of its included studies reported cigarette-cessation outcomes. This dated review separates exposure measurements from treatment effectiveness; it does not establish current products’ long-term disease risks.[2]
Selected-source overview · Independent review pendingPublished questions
Is heated tobacco the same product category as a liquid e-cigarette?
Selected-source overview · Independent review pending. Read the evidence context.
No. Heated products use tobacco leaf or sheet; e-cigarettes heat liquid. Their composition, devices and research should be distinguished even when both produce inhaled aerosol.[1]
Evidence behind this answer
- Heated tobacco products
official health guidance · 2024
Selected relevant original official page passages inspected · Definitions, nicotine, secondhand emissions and research limits; older regulatory paragraphs not used as current
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does an IQOS reduced-exposure claim establish lower disease incidence?
Selected-source overview · Independent review pending. Read the evidence context.
No. FDA’s April 2026 US renewal permits a specific complete-switching exposure claim for named products. Exposure and disease-risk claims answer different questions.[4]
Evidence behind this answer
- FDA renews authorization for five IQOS products with exposure-modification claims
official health guidance · 2026
Selected relevant original official page passages inspected · April 17, 2026 order; exact exposure wording and product-specific limitation
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Did the 2022 heated-tobacco review establish smoking-cessation effectiveness?
Selected-source overview · Independent review pending. Read the evidence context.
No. None of its included studies reported cigarette smoking cessation. Lower measured toxicant exposure is a separate finding.[2]
Evidence behind this answer
- Heated tobacco products for smoking cessation and reducing smoking prevalence
systematic review · 2022
Original public review summary and selected abstract passages inspected; no independent full-review appraisal · Public summary and abstract: exposure, no cessation studies, bias and Japanese sales
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are all harmful substances necessarily lower in heated-tobacco aerosol?
Selected-source overview · Independent review pending. Read the evidence context.
No. The composition review reported some constituents at higher levels and others absent from the measured cigarette mixture. A reduction in some chemicals does not describe every hazard.[3]
Evidence behind this answer
- Heated tobacco products: insights into composition and toxicity
original review · 2023
Original abstract and selected full-text review passages inspected; no independent systematic appraisal · Abstract and selected composition/research-funding discussion
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Are heated-tobacco emissions equivalent to clean air for bystanders?
Selected-source overview · Independent review pending. Read the evidence context.
No. CDC describes exposure to chemicals also found in cigarette smoke and calls for further health research. Lower levels than smoke do not establish clean-air equivalence.[1]
Evidence behind this answer
- Heated tobacco products
official health guidance · 2024
Selected relevant original official page passages inspected · Definitions, nicotine, secondhand emissions and research limits; older regulatory paragraphs not used as current
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can consumers interpret reduced exposure as a stronger health claim?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. The 2018 consumer-study analysis described that inference. It concerns message interpretation and cannot itself demonstrate a reduction in disease.[6]
Evidence behind this answer
- Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims
original research analysis · 2018
Original indexed abstract excerpt inspected; direct retrieval unavailable; no full-text appraisal · Original indexed abstract conclusion on manufacturer consumer studies
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
The US decision concerns complete switching and named products
On April 17, 2026, FDA renewed exposure-modification orders for five specified IQOS system and HeatSticks products. The authorized statement concerns a reduction in harmful-chemical exposure when adults switch completely from conventional cigarettes. It is tied to submission tracking numbers and can be withdrawn if the population-health standard is no longer met. This checked US decision does not automatically authorize disease-risk claims, claims about every heated product, or statements about bystander exposure.[4]
Exposure markers are useful but narrower than disease outcomes
The Cochrane review examined measures including a nicotine-related carcinogen metabolite and carbon-monoxide exposure. Differences over short follow-up can show that exposure changed without showing how many cancers or heart attacks will occur later. Adverse-event comparisons were limited by bias and imprecision. Lack of detected serious events in a small trial is not evidence that rare or delayed harms are absent. The public summary and abstract were inspected here rather than independently appraising every trial.[2]
WHO’s concerns include how exposure claims are understood
WHO’s July 2020 statement cautioned that reduced exposure need not translate into reduced health risk, particularly if other toxins remain. It also stressed that a US market decision rests on jurisdiction-specific considerations. The statement addresses an earlier FDA decision; the 2026 renewal is described separately here. Read the date and type of claim together. A regulator’s permitted wording and a public-health organization’s caution can concern different standards without making either an all-purpose product endorsement.[5]
Consumers can infer more than a claim actually says
Popova and colleagues’ 2018 analysis of manufacturer consumer studies reported that adults interpreted reduced-exposure messages as suggesting reduced disease risk. This explains a communication concern, rather than proving the device’s clinical effects. The analysis used the available studies and an earlier product context, and current messages may differ. A reader should identify whether a statement describes measured chemicals, disease incidence or a permitted advertisement before treating those statements as interchangeable.[6]
The route still creates bystander exposure questions
WHO cautions that a change in exposure does not establish reduced disease risk. That principle also limits statements about shared indoor air: a user’s exposure measurement cannot settle another person’s dose or chronic outcomes. Research needs to distinguish the product, use frequency and the population being observed. Stopping all tobacco exposure, replacing cigarettes completely and continuing multiple products are separate scenarios. A general smoke-free label should not obscure which scenario a claim actually concerns.[5]
References
- Heated tobacco products
Official health guidance
CDC · Content/publication date: 2024
Accessed: 2026-10-13 UTC · Selected relevant original official page passages inspected
Cited sections: Definitions, nicotine, secondhand emissions and research limits; older regulatory paragraphs not used as current - Heated tobacco products for smoking cessation and reducing smoking prevalence
Systematic review
Cochrane · Content/publication date: 2022
Accessed: 2026-10-13 UTC · Original public review summary and selected abstract passages inspected; no independent full-review appraisal
Cited sections: Public summary and abstract: exposure, no cessation studies, bias and Japanese sales - Heated tobacco products: insights into composition and toxicity
Original review
Upadhyay and colleagues · Content/publication date: 2023
Accessed: 2026-10-13 UTC · Original abstract and selected full-text review passages inspected; no independent systematic appraisal
Cited sections: Abstract and selected composition/research-funding discussion - FDA renews authorization for five IQOS products with exposure-modification claims
Official health guidance
FDA · Content/publication date: 2026
Accessed: 2026-10-13 UTC · Selected relevant original official page passages inspected
Cited sections: April 17, 2026 order; exact exposure wording and product-specific limitation - WHO statement on heated tobacco and the US FDA IQOS decision
Official health guidance
WHO · Content/publication date: 2020
Accessed: 2026-10-13 UTC · Selected relevant original official page passages inspected
Cited sections: 2020 statement: exposure versus risk, jurisdiction and tobacco cessation - Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims
Original research analysis
Popova and colleagues · Content/publication date: 2018
Accessed: 2026-10-13 UTC · Original indexed abstract excerpt inspected; direct retrieval unavailable; no full-text appraisal
Cited sections: Original indexed abstract conclusion on manufacturer consumer studies
Scope & review
- Population
- Adults comparing tobacco heating with cigarettes or abstinence; includes bystander and youth exposure boundaries
- Exposure or intervention
- Heated tobacco products
- Comparison
- Tobacco heating versus liquid vaping and cigarette combustion; complete switching versus dual use and abstinence; exposure modification versus disease-risk reduction
- Outcomes
- Product understanding, exposure, dependence, impairment, disease and source-specific cessation outcomes
- Timeframe
- Immediate effects versus selected short-term trials and longer-term disease evidence; dates and access limits are source-specific
- Jurisdiction
- US CDC and FDA April 17, 2026 IQOS orders, checked October 13, 2026 UTC; WHO international guidance and selected research
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-13 UTC: Added an edition 4.4 educational explanation; selected sources checked 2026-10-13 UTC, qualified expert review pending.
What this article still leaves open
- How do independent long-term disease findings differ by device and use pattern?
- How should exposure messages communicate complete switching without implying safety?
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.